ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0991

Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database

Dongxing Xie1, Qiao Jiang2, Yuqing Wang2, Huizhong Long2, Hu Chen3, Jie Wei4, Xiaoxiao Li5, Haibo Wang6, Chao Zeng7 and Guanghua Lei7, 1Xiangya Hospital, Central South University, Changsha, China, 2Xiangya Hospital, Changsha, China, 3Tibet Autonomous Region People’s Hospital, Lhasa, China, 4Health Management Center, Xiangya Hospital Central South University, Changsha, China, 5Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, 6China Standard Medical Information Research Center, Shenzhen, China, 7Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China

Meeting: ACR Convergence 2023

Keywords: Arthroplasty, rheumatoid arthritis, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 13, 2023

Title: (0965–0992) Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: For end-stage inflammatory arthritis (IA) including rheumatoid arthritis (RA) and spondyloarthritis (SpA), joint arthroplasty is the only treatment option, but is considered to be a failure of medical treatment. Country-level socioeconomic factors play an important role in treatment options and long-term outcomes of IA. Though trends in arthroplasty utilization for RA and SpA have been well-studied in high-income countries, the data are still scarce in low- or middle-income countries. Understanding the trends in arthroplasty utilization in low- or intermediate-income countries would add epidemiological data on this topic and have important implications for health policy in these countries. Using the Chinese national inpatient database (i.e., the Hospital Quality Monitoring System), we aimed to examine trends in arthroplasty utilization among patients with RA, SpA, and a composite group of the IA, compared with these trends among those without IA.

Methods: Patients receiving elective primary total knee arthroplasty and total hip arthroplasty for IA or non-inflammatory conditions between 2013 and 2019 were included. The International Classification of Diseases, Tenth Revision codes were used to identify RA and SpA. Comparisons between groups were performed using the Student’s t-test for continuous variables and chi-square test for categorical variables. A generalized estimating equation model was used to examine trends over time.

Results: Of 358,891 arthroplasties performed between 2013 and 2019, 3.8% (13,747) were performed for IA (Table 1). From 2013 to 2019, the number of arthroplasties for IA slightly increased from 1,596 to 1,834 (average yearly increase rate, 2.0%), and the number of arthroplasties for non-inflammatory conditions significantly increased from 34,712 to 51,907 (average yearly increase rate, 5.9%) (P < 0.001) (Figure 1). The proportion of arthroplasty for IA declined from 4.4% to 3.4%. In the IA group, the mean age at arthroplasty increased from 55.8 years to 59.5 years (P < 0.001), and a similar result was also found in the non-inflammatory group. The number of arthroplasties for RA increased from 1,366 to 1,701 (average yearly increase rate, 3.2%) (P < 0.001). This contrasted with the findings of SpA (average yearly decrease rate, 7.5%) (P < 0.001) (Figure 2). Age at arthroplasty increased from 58.5 years to 60.5 years in the RA group (P < 0.001) and from 39.5 years to 47.2 years in the SpA group (P < 0.001). In addition, a decrease in the proportion of arthroplasty before 50 years among RA and SpA patients was observed.

Conclusion: This nationwide inpatient-based study found that arthroplasty utilization slightly increased in RA, but significantly decreased in SpA in China. The increase in arthroplasty utilization for RA may be driven by the popularity of arthroplasty because a significant decrease in the proportion of arthroplasty for RA was observed. The decrease in arthroplasty utilization for SpA is conceivable given that economic development expanded the access to medical resource. Additionally, an increase in age at arthroplasty for RA and SpA was also found, suggesting long-term outcomes of RA and SpA are improving.

Supporting image 1

Figure 1. Trends in the number of arthroplasties in the non-inflammatory group (A) and the IA group (B).

Supporting image 2

Figure 2. Trends in the number of arthroplasties in the RA group and the SpA group.

Supporting image 3

Table 1. Characteristics of patients with RA, SpA, IA and non-inflammatory conditions who received TKA or THA


Disclosures: D. Xie: None; Q. Jiang: None; Y. Wang: None; H. Long: None; H. Chen: None; J. Wei: None; X. Li: None; H. Wang: None; C. Zeng: None; G. Lei: None.

To cite this abstract in AMA style:

Xie D, Jiang Q, Wang Y, Long H, Chen H, Wei J, Li X, Wang H, Zeng C, Lei G. Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/trends-in-arthroplasty-utilization-for-inflammatory-arthritis-including-rheumatoid-arthritis-and-spondyloarthritis-in-china-analysis-of-a-large-national-database/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trends-in-arthroplasty-utilization-for-inflammatory-arthritis-including-rheumatoid-arthritis-and-spondyloarthritis-in-china-analysis-of-a-large-national-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology